NuSep licences gels
Wednesday, 17 September, 2008
NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.
The third party had offered to acquire NuSep's gels business outright or to license the technology.
It was decided that licensing the technology would provide the best return for shareholders, the company said.
The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.
NuSep also supplies research grade biological products such as human IgG and albumin.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
